Nutriband formalizes exclusive Aversa Fentanyl partnership with Kindeva; potential $80-200M US sales

NutriBand Inc.

Signed addendum formalizing exclusive development partnership for Aversa Fentanyl with Kindeva Drug Delivery.
Partnership based on shared development costs in exchange for milestone payments.
Aversa Fentanyl combines Nutriband's abuse-deterrent technology with Kindeva's FDA-approved fentanyl patch.
Estimated peak annual US sales potential of $80M to $200M.
AVERSA technology protected by patents in 46 countries including US, Europe, Japan.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.